无支架三维培养保留慢性淋巴细胞白血病B-T细胞交互并实现药敏分析
研究建立来自慢性淋巴细胞白血病(CLL)患者样本的无支架三维淋巴瘤球体(CLL-PDLS),可保留肿瘤B细胞与自体T细胞交互,维持6天活性与增殖,B细胞约占90%、T细胞约10%,并用于伊布替尼和维奈克拉药敏评估。
要点
- CLL-PDLS由肿瘤B细胞与自体T细胞自组织成三维圆盘结构,可培养至6天。
- T细胞呈现CD4+和CD8+亚群的活化与耗竭表型,表达PD-1、CD25、TIGIT和CD69。
- 该模型保留B-T细胞动态交互,可用于伊布替尼和维奈克拉等常规治疗反应评估。
核心结论
- CLL-PDLS三维球体模型可捕捉CLL中B-T细胞交互的关键功能方面,并部分重现微环境特征。
- 该模型为临床前治疗评估提供了有前景的平台。
研究设计与样本
- 研究利用CLL患者样本建立无支架三维淋巴瘤球体(CLL-PDLS),纳入肿瘤B细胞与自体T细胞。
- 培养在最佳条件下维持至6天,并评估细胞活性、增殖、免疫表型及对伊布替尼和维奈克拉的反应。
主要发现
- CLL球体中肿瘤B细胞约占90%,T细胞约占10%,细胞组成保持稳定。
- T细胞在CD4+和CD8+亚群中表现活化与耗竭表型,包括PD-1、CD25、TIGIT和CD69表达。
- 培养6天内保持细胞活性和高增殖活性,并保留B-T细胞间动态交互。
关键数值与推荐
- CLL-PDLS可维持至6天,肿瘤B细胞约占90%,T细胞约占10%。
- T细胞表达PD-1、CD25、TIGIT和CD69,覆盖CD4+和CD8+亚群。
- 模型经伊布替尼和维奈克拉常规治疗反应评估验证。
临床怎么用
- 该模型可用于CLL患者来源样本的临床前药敏筛查与治疗反应评估。
- 可支持研究肿瘤微环境中B-T细胞交互及免疫表型变化。
- 需进一步研究以确认其临床预测价值。
局限性
- 培养时间最长6天,可能限制长期药物反应观察。
- 模型仅部分重现微环境特征,文中未报告其他验证细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient-derived lymphoma spheroids from CLL samples (CLL-PDLS), which recapitulate the cross-talk between malignant cells and the autologous immune microenvironment enabling efficient drug screening for further studies. CLL spheroids incorporate tumour B cells together with autologous T cells, which self-organize into a three-dimensional (3D) disc-shaped structure. Cultures can be maintained for up to 6 days under optimal conditions, preserving cell viability and high proliferative activity. T cells exhibit a range of activation and exhaustion phenotypes across both CD4+ and CD8+ subsets, including expression of Programmed Cell Death Protein 1 (PD-1), CD25, T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD69. The cellular composition remains stable, with tumour B cells representing approximately 90% of the population and T cells comprising 10%. The model was further validated by assessing responses to conventional therapies, including ibrutinib and venetoclax. In conclusion, this 3D spheroid model captures key functional aspects of B-T interactions in CLL, maintaining the dynamic interactions between malignant B cells and their autologous immune components, partially reproducing microenvironmental features, and offering a promising platform for preclinical therapeutic evaluation.
引用
- Playa-Albinyana H, Giró A, Piñeyroa JA, et al. Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling. Br J Haematol. 2026. PMID: 42360285. doi:10.1111/bjh.70635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。